Q1 Fiscal Year 2023
- Broad-based equipment order growth in double-digit percentages; equipment book-to-bill ratio of 1.36
- Comparable revenue decline of 4.5% from strong prior-year quarter due to markedly lower revenue from rapid COVID-19 antigen tests, as expected; excluding antigen tests, comparable revenue growth of 0.7%
- Imaging showed solid comparable revenue growth of 5.2% and a clear improvement in adjusted EBIT margin of 100 basis points year-over-year to 20.9%
- Diagnostics revenue down 23.7% on a comparable basis, mainly due to a markedly lower contribution from rapid COVID-19 antigen tests and the COVID-19 situation in China; adjusted EBIT margin slightly negative at -2.2% due to transformation costs
- Varian comparable revenue down 4.5% and adjusted EBIT margin of 14.5%, hampered by delays at a supplier that have since been resolved
- Advanced Therapies comparable revenue growth at a solid 5.0% and adjusted EBIT margin of 11.6%
- Lower overall adjusted EBIT margin of 12.7% weighed down by lower contributions from rapid COVID-19 antigen tests, cost increases – particularly for procurement and logistics – and transformation costs in Diagnostics
- Adjusted basic earnings per share below prior-year quarter at €0.47
Outlook for Fiscal Year 2023
We confirm our expectation for comparable revenue growth of -1% to 1% (6% to 8% excluding revenue from rapid COVID-19 antigen tests) and adjusted basic earnings per share of €2.00 to €2.20.
Bernd Montag, CEO of Siemens Healthineers AG:
»Our consistently strong equipment order growth underscores the trust that customers have in our innovation leadership. This gives us great momentum to achieve our full-year targets.«